ABSTRACT
Objective:To investigate therapeutic effect of cisplatin sequential recombinant human vascular endostatin thoracic perfusion in treatment of malignant pleural effusion.Methods:A total of 80 patients with malignant pleural effusion in Maoming People's Hospital from January 2018 to February 2021 were enrolled, and all patients were divided into 2 groups according to the random number table methods, each group with 40 cases. The control group was treated with small-bore catheter minimally invasive drainage combined with cisplatin thoracic perfusion, and the study group was treated with small-bore catheter minimally invasive drainage combined with cisplatin sequential recombinant human vascular endostatin thoracic perfusion. And then the clinical efficacy, expressions of vascular endothelial growth factor (VEGF) expression, pain degree and adverse reactions were compared of both groups.Results:The treatment efficacy rate of the study group was higher than that of the control group [90% (36/40) vs. 75% (30/40)], and the difference was statistically significant ( χ2 = 5.04, P < 0.05). After treatment, the level of VEGF in pleural fluid and serum of the study group was lower than that of the control group [(304±106) pg/ml vs. (598±159) pg/ml,(103±43) pg/ml vs. (189±49) pg/ml], and the difference was statistically significant ( t = 6.62, P < 0.001; t = 6.23, P < 0.001). After treatment, the visual analogue scale (VAS) score of the study group was lower than that of the control group [(3.7±0.3) scores vs. (4.4±0.7) scores], and the difference was statistically significant ( t = 2.10, P < 0.05). The incidence of adverse reactions including stethalgia, fever, nausea and vomiting in both groups had no statistically significant differences (all P > 0.05). Conclusions:Cisplatin sequential recombinant human vascular endostatin thoracic perfusion combined with small-bore catheter minimally invasive drainage can effectively ameliorate clinical symptoms, inhibit the expression of VEGF, and alleviate pain degree with no serious adverse reactions in patients with malignant pleural effusion.
ABSTRACT
Objective: To observe the clinical efficacy of intraperitoneal injection of recombinant human vascular endostatin combined with 5-fluorouracil (5-FU) in patients with malignant ascites, and to detect the change of percentage of endothelial cells (ECs) in ascites before and after treatment, in order to explore the clinical value of endothelial cells in treatment of malignant ascites. Methods: Thirty-nine patients with malignant ascites received two cycles of intraperitoneal inject of endostar combined with 5-FU treatment. The clinical response, change of quality of life (QOL) and the adverse events were assessed. The flow cytometry was used to detect the level of endothelial cells in malignant ascites before and after treatment. Results: In 39 patients, the objective response rate (complete response and partial response) was 43.6% (1 7/39); the rate of QOL improvement was 53.8% (21/39). The rates of grades 3-4 adverse events were low, including leukopenia in 2 patients (5.1%, 2/39), thrombocytopenia in 1 patient (2.6%, 1/39), anemia in 2 patients (5.1%, 2/39), nausea in 4 patients (10.3%, 4/39), and diarrhea in 1 patient (2.6%, 1/39). In 16 patients achieveing clinical response, the percentage of endothelial cells in malignant ascites before treatment was significantly higher than that after treatment [(0.22±0.06)% vs (0.12±0.08) %, P = 0.005]. In 21 patients achieveing improvement in QOL, the percentage of endothelial cells in malignant ascites before treatment was also significantly higher than that after treatment [(0.1 9±0.08)% vs (0.1 3±0.08) %, P = 0.032]. The percentages of endothelial cells in malignant ascites in patients not achieveing clinical response and improvement in QOL after treatment had no significant changes (P = 0.11 4, P = 0.359). Conclusion: Intraperitoneal inject of endostar combined with 5-FU treatment can effectively control the malignant ascites and improve the QOL. The level of endothelial cells in malignant ascites may become a clinical marker to predict the response to the treatment of malignant ascites.
ABSTRACT
Objective To explore the effect of recombinant human endostatin combined with transcatheter arterial chemoembolization on vascular endothelial growth factor (VEGF), hypoxia inducible factor-1 alpha(HIF-1α), osteopontin (OPN) and connective tissue growth factor (CTGF) levels in serum of HCC patients.Methods 90 cases of primary liver cancer patients were randomly divided into control group and observation group, 45 cases in each group.The control group received the routine chemotherapy of hepatic artery embolization, and the observation group received recombinant human vascular endostatin combined with hepatic arterial chemoembolization.The serum levels of VEGF, HIF-1α, OPN, and CTGF were detected by enzyme-linked immunosorbent assay before treatment, 3 days and 5 days after operation, then the correlations were analyzed.Results The VEGF, HIF-1α, OPN, CTGF levels after 3 days and 5 days were higher than those before surgery in control group and observation group (P<0.05), the above indexes after 5 days were lower than those after 3 days in both groups (P<0.05), and VEGF, OPN and CTGF levels except for HIF-1αin observation group were significantly lower than those in control group after 5 days (P<0.05).There existed significant positive correlation between serum VEGF and HIF-1α, OPN, CTGF concentration levels(r=0.985, 0.995, 0.959,P<0.05) in 90 cases of liver cancer patients, highly positive correlation between HIF-1αand OPN, CTGF levels (r=0.842,0.874, P<0.05), and moderately positive correlation between OPN and CTGF concentrations (r=0.755,P<0.05).Conclusion The efficacy of recombinant human vascular endostatin combined with transcatheter arterial chemotherapy and embolization in the treatment of primary hepatocellular carcinoma is good.There exsits closely correlation of VEGF, HIF-1α, OPN and CTGF levels in serum, which could reflect clinical efficacy.
ABSTRACT
Objective To study the clinical effects and side effects of recombinant human vascular endostatin combined with pemetrexed and cisplatin in the treatment of advanced lung adenocarcinoma.Methods Forty-seven patients with advanced lung adenocarcinoma were recruited from Jan 2011 to Jan 2013,and they were randomly divided into experimental group and control group.The experimental group (n =24) was added with recombinant human vascular endostatin based on pemetrexed and cisplatin,whereas the control group(n =23) was administered with pemetrexed and cisplatin only.The objective response rate (ORR),disease control rate (DCR),progressive disease (PD) rate,progression-free survival (PFS),overall survival (OS) and the side effects of 2 groups were evaluated.Results In the experimental group,ORR,DCR,PD rate,PFS and OS were 41.7 ％ (10/24),79.2 ％ (19/24),20.8 ％ (5/24),8.0 months and 12.5 months respectively,while those of control group were 34.7 ％ (8/23),47.8 ％ (11/23),52.2 ％ (12/23),6.2 months and 10.0 months.DCR,PD rate and PFS of experimental group had significant differences compared with control group (P ＜ 0.05).OS of experimental group had no significant difference compared with control group (P ＞ 0.05).The side effects of 2 groups were mainly hematologic toxicities,digestive reactions and fatigue,and the incidence rates were not significantly different between 2 groups (P ＞ 0.05).Conclusions Recombinant human vascular endostatin combined with pemetrexed and cisplatin in treatment of patients with advanced lung adenocarcinoma improves the DCR,decreases the PD rate,prolongs the PFS.There is an increasing trend in the OS of experimental group,and with tolerable side effects.
ABSTRACT
Objective: To evaluate the short-term effect and the survival of patients with advanced non-small cell lung cancer (NSCLC) after receiving recombinant human vascular endostatin (Endostar) therapy in combination with standard platinum-based regimen. Methods: Forty eligible patients were recruited from May 2007 to April 2009, and they received Endostar (15 mg/d, d 1 to d 14, per 3 weeks a cycle) plus platinum-based regimen (per 3 weeks a cycle) for 4-6 cycles. The objective response rate (ORR), disease control rate (DCR), progression-free survival (PFS) and the overall survival (OS) were evaluated. Subgroup analysis was based on the clinicopathological features. Results: Of 40 patients, 37 could be evaluated for short-term response. The ORR was 29.7%, and the DCR was 81.8%; the median PFS was 11.1 months, and the median OS was 23.0 months. Subgroup analysis showed that PFS was associated with histology (hazard ratio = 0.366; 95% confidence interval: 0.160-0.840; P = 0.018) and the clinical stage (hazard ratio = 0.405; 95% confidence interval: 0.174-0.942; P = 0.036). The gender, age, histology and the clinical stage were not associated with OS. Conclusion: Treatment of Endostar in combination with standard platinum-based regimen may prolong the PFS and OS of patients with advanced NSCLC. Copyright© 2011 by the Editorial Board of Tumor.
ABSTRACT
Objective: To investigate the short-term efficacy and safety of recombinant human endostatin YH-16 combined with navelbine and cisplatin in the first line treatment of advanced non-small cell lung cancer (NSCLC) and its effect on the survival. Methods: Eighty patients with advanced NSCLC were recruited from May, 2007 and May, 2010, and they were randomly divided into study group (n=40, treated with YH-16 combined with navelbine and cisplatin) and conrol group (n=40, treated with navelbine plus cisplatin). The short-term efficacy and adverse effects were evaluated every six weeks (one chemotherapy cycle was given every 3 weeks). The survival was calculated. Results: Thirty-nine patients in the study group and 36 patients in the control group were evaluable. The stable disease rate in the study group was higher than that in the control group (53.8% vs 27.8%, χ2=5.25, P=0.022), and the clinical benefit rate was also higher (76.9% vs 55.6%, χ2=3.85, P=0.050). The progressive disease rate in the study group was lower than that in the control group (23.1% vs 44.4%, χ2=3.85, P=0.050). There were no significantly differences in time to progression and overall survival between the two groups (P>0.05). Most adverse effects were hematologic toxicities and digestive reactions, and the incidence rate was not significantly different between the two groups. The incidence rate of abnormal electrocardiogram in asymptomatic person was higher in the study group than that in the control group (χ2=16.27, P=0.001). Conclusion: YH-16 combined with navelbine and cisplatin as the first line treatment for advanced NSCLC can improve the stable disease rate, and the clinical benefit rate, decrease the progressive disease rate, and increase the rate, of cardiac electrophysiological abnormality, but the overall safety is acceptable.